Pharmaceutical company Novartis has brought High Court proceedings against two rival firms alleging infringement of its patent on a drug for treating multiple sclerosis.
Switzerland-based Novartis AG, and its Irish affiliate, Novartis Ireland Ltd, claim Accord and Mylan are breaching their patent on Gilenya.The medicine is used in the treatment of relapsing-remitting multiple sclerosis, and contains the active ingredient fingolimod.
Novartis says Gilenya is “one of the most important and valuable products” in its portfolio, contributing more than $2.7 billion of net sales in 2021.
Accord markets its version of the medicine under the name Fingolimod Accord, while the Mylan version is called Fingolimod Mylan.
Secret Teacher: Too many school leaders bow to parent power. They bend the knee or rarely back their staff
Oscars 2025: Was Adrien Brody’s speech the longest ever, was Conan O’Brien funny and eight other key questions
Pancake Tuesday: The only recipe you need for making an easy, better batter
‘Where I come from, people don’t do medicine. It’s not on your radar’: how a new generation of doctors is being trained
Novartis is suing Accord Healthcare SLU, with its principal office in Barcelona, Spain, and its Irish representative Accord Healthcare Ltd.
It is separately suing Mylan Healthcare Ltd, which is part of the Viatris group of companies, Mylan Healthcare Ireland Ltd and McDermott Laboratories, trading as Gerard Laboratories which itself trades as Mylan Dublin and markets the product in Ireland.
The two companies deny the Novartis claims.
The cases were admitted to the High Court’s fast-track Commercial Division on Monday by Mr Justice Denis McDonald, on consent between the parties.
Jonathan Newman SC, for Novartis, said his client was reserving its position in relation to seeking an injunction preventing the marketing of the rival medicines pending the hearing of the patent dispute.
The judge approved directions for progressing the cases and adjourned them to April next.
